DP-VPA Uses, Dosage, Side Effects and more
DP-VPA is D-Pharm's proprietary lipid modified version of valproic acid (VPA) that demonstrate that DP-VPA is well-tolerated in patients with resistant epilepsy and has a marked effect on reducing seizure frequency.
| Trade Name | DP-VPA |
| Generic | DP-VPA |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
Investigated for use/treatment in bipolar disorders, epilepsy, and migraine and cluster headaches.
How DP-VPA works
DP-VPA is a new chemical entity (NCE) utilising D-Pharm's proprietary technology, Regulated Activation of Prodrugs (D-RAPTM). DP-VPA comprises VPA linked to a phospholipid moiety to form a prodrug that may be specifically cleaved by phospholipase A2 (PLA2), an enzyme specifically up-regulated in firing neurons. With a seizure imminent, VPA is preferentially released at the site of pathology until PLA2 hyperactivation subsides, enabling precise control over drug action.
